Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    nivolumab and yervoy | Phase 3
Show Display Options
Rank Status Study
1 Active, not recruiting Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
Condition: Unresectable or Metastatic Melanoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Placebo for Nivolumab;   Biological: Placebo for Ipilimumab
2 Recruiting A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab Combined With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)
Condition: Recurrent Glioblastoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Bevacizumab
3 Recruiting Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Conditions: Advanced Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Sunitinib
4 Not yet recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Dabrafenib;   Drug: Trametinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment

Indicates status has not been verified in more than two years